1. Home
  2. PTN
  3. PTN News

Latest Palatin Technologies Inc. (PTN) News on April 24, 2025

Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide
PTN

PR Newswire

7 days ago

Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide

PTN

MT Newswires

10 days ago

Top Premarket Gainers

Palatin Appeals NYSE American Notice of Delisting
PTN

PR Newswire

10 days ago

Palatin Appeals NYSE American Notice of Delisting

PTN

MT Newswires

13 days ago

Top Midday Decliners

PTN

MT Newswires

13 days ago

Palatin Technologies Gets Delisting Notice from NYSE American, Plans to Appeal

Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal
PTN

PR Newswire

13 days ago

Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal

Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting
PTN

PR Newswire

14 days ago

Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting

Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study
PTN

PR Newswire

24 days ago

Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study

Palatin’s UC therapy prompts clinical remission in a third of patients
PTN

Clinical Trials Arena

a month ago

Palatin’s UC therapy prompts clinical remission in a third of patients

PTN

MT Newswires

a month ago

Palatin Technologies' Ulcerative Colitis Drug Candidate Shows Positive Results in Phase 2 Study

Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177
PTN

PR Newswire

a month ago

Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177

Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency
PTN

PR Newswire

a month ago

Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency

Here's Why Palatin Technologies (PTN) Is a Great 'Buy the Bottom' Stock Now
PTN

Zacks

a month ago

Here's Why Palatin Technologies (PTN) Is a Great 'Buy the Bottom' Stock Now

PTN

Thomson Reuters StreetEvents

2 months ago

Q2 2025 Palatin Technologies Inc Earnings Call

Palatin Technologies Inc (PTN) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ...
PTN

GuruFocus.com

2 months ago

Palatin Technologies Inc (PTN) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ...

Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update
PTN

PR Newswire

2 months ago

Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update

Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025
PTN

PR Newswire

2 months ago

Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025

Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement
PTN

PR Newswire

3 months ago

Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement

Palatin concludes Phase II trial of combination therapy for obesity
PTN

Clinical Trials Arena

3 months ago

Palatin concludes Phase II trial of combination therapy for obesity

Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide
PTN

PR Newswire

3 months ago

Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide

Palatin Provides Update on Anticipated 2025 Corporate Milestones
PTN

PR Newswire

3 months ago

Palatin Provides Update on Anticipated 2025 Corporate Milestones

Palatin reports positive Phase 2b results in diabetic nephropathy
PTN

TipRanks

4 months ago

Palatin reports positive Phase 2b results in diabetic nephropathy

Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy
PTN

PR Newswire

4 months ago

Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy

PTN

MT Newswires

4 months ago

Palatin Technologies Signs Inducement Agreement for Gross Proceeds of $3.4 Million for Investor's Excercise of Warrants

Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds
PTN

PR Newswire

4 months ago

Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds

Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis
PTN

PR Newswire

5 months ago

Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis

PTN

Thomson Reuters StreetEvents

5 months ago

Q1 2025 Palatin Technologies Inc Earnings Call

Palatin Technologies Inc (PTN) Q1 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue ...
PTN

GuruFocus.com

5 months ago

Palatin Technologies Inc (PTN) Q1 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue ...

Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results
PTN

PR Newswire

5 months ago

Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results

Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024
PTN

PR Newswire

6 months ago

Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024

Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024
PTN

PR Newswire

6 months ago

Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024

Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity
PTN

PR Newswire

6 months ago

Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity

Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium
PTN

PR Newswire

6 months ago

Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium

Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium
PTN

PR Newswire

6 months ago

Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium

PTN

MT Newswires

7 months ago

Palatin Technologies Gets NYSE American Noncompliance Notice -- Shares Fall After Hours

Palatin Receives Notice of Non-Compliance from NYSE American
PTN

PR Newswire

7 months ago

Palatin Receives Notice of Non-Compliance from NYSE American

PTN

Thomson Reuters StreetEvents

7 months ago

Q4 2024 Palatin Technologies Inc Earnings Call

Palatin Technologies Inc (PTN) Q4 2024 Earnings Call Transcript Highlights: Strategic Moves and ...
PTN

GuruFocus.com

7 months ago

Palatin Technologies Inc (PTN) Q4 2024 Earnings Call Transcript Highlights: Strategic Moves and ...

Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones
PTN

PR Newswire

7 months ago

Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones

Palatin Technologies Inc (PTN) Q4 2024 Earnings Report Preview: What To Expect
PTN

GuruFocus.com

7 months ago

Palatin Technologies Inc (PTN) Q4 2024 Earnings Report Preview: What To Expect

Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results
PTN

PR Newswire

7 months ago

Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results

Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones
PTN

PR Newswire

7 months ago

Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones

PTN

MT Newswires

8 months ago

Palatin Technologies' Phase 3 Trials for Dry Eye Disease Treatment Receive FDA Confirmation on Protocols, Endpoints

FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)
PTN

PR Newswire

8 months ago

FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)

Palatin Technologies doses first subject in Phase II obesity treatment trial
PTN

Clinical Trials Arena

8 months ago

Palatin Technologies doses first subject in Phase II obesity treatment trial

First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity
PTN

PR Newswire

8 months ago

First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity

Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds
PTN

PR Newswire

10 months ago

Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds

Palatin initiates Bremelanotide-PDE5i Phase II trial for ED
PTN

Clinical Trials Arena

10 months ago

Palatin initiates Bremelanotide-PDE5i Phase II trial for ED

Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)
PTN

PR Newswire

10 months ago

Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)

Palatin Technologies commences Phase II study of obesity treatment
PTN

Clinical Trials Arena

10 months ago

Palatin Technologies commences Phase II study of obesity treatment

PTN

MT Newswires

10 months ago

Palatin Technologies Starts Phase 2 of Obesity Treatment Study

Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity
PTN

PR Newswire

10 months ago

Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity

Lotto 6/49 - $64 million up for grabs in the next draw!
PTN

CNW Group

10 months ago

Lotto 6/49 - $64 million up for grabs in the next draw!

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture
PTN

Simply Wall St.

10 months ago

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Seoul says it will resume loudspeaker propaganda against North
PTN

AFP

10 months ago

Seoul says it will resume loudspeaker propaganda against North

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend
PTN

Simply Wall St.

10 months ago

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m
PTN

Simply Wall St.

10 months ago

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week
PTN

Barrons.com

10 months ago

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend
PTN

Simply Wall St.

10 months ago

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued
PTN

Simply Wall St.

10 months ago

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

Palatin Technologies (PTN) Upgraded to Buy: What Does It Mean for the Stock?
PTN

Zacks

a year ago

Palatin Technologies (PTN) Upgraded to Buy: What Does It Mean for the Stock?

PTN

GuruFocus.com

a year ago

Palatin Technologies Inc (PTN) (Q3 2024) Earnings Call Transcript Highlights: Navigating ...

PTN

Thomson Reuters StreetEvents

a year ago

Q3 2024 Palatin Technologies Inc Earnings Call

Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
PTN

PR Newswire

a year ago

Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024
PTN

PR Newswire

a year ago

Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024

Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity
PTN

PR Newswire

a year ago

Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity

Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024
PTN

PR Newswire

a year ago

Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024

10 Micro-Cap Healthcare Stocks Insiders Are Buying
PTN

Insider Monkey

a year ago

10 Micro-Cap Healthcare Stocks Insiders Are Buying

Palatin (PTN) Up 15% on Results From Dry Eye Disease Study
PTN

Zacks

a year ago

Palatin (PTN) Up 15% on Results From Dry Eye Disease Study

Palatin Technologies Eyes Growing $6B Dry Eye Disease Market With Late-Stage Study Data
PTN

Benzinga

a year ago

Palatin Technologies Eyes Growing $6B Dry Eye Disease Market With Late-Stage Study Data

Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024
PTN

PR Newswire

a year ago

Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024

Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
PTN

PR Newswire

a year ago

Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

Palatin Technologies, Inc. (AMEX:PTN) Q2 2024 Earnings Call Transcript
PTN

Insider Monkey

a year ago

Palatin Technologies, Inc. (AMEX:PTN) Q2 2024 Earnings Call Transcript

PTN

Thomson Reuters StreetEvents

a year ago

Q2 2024 Palatin Technologies Inc Earnings Call

Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
PTN

PR Newswire

a year ago

Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024
PTN

PR Newswire

a year ago

Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024

Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
PTN

PR Newswire

a year ago

Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

Palatin Announces Closing of $10 Million Registered Direct Offering
PTN

PR Newswire

a year ago

Palatin Announces Closing of $10 Million Registered Direct Offering

Are Investors Undervaluing The Container Store Group, Inc. (NYSE:TCS) By 50%?
PTN

Simply Wall St.

a year ago

Are Investors Undervaluing The Container Store Group, Inc. (NYSE:TCS) By 50%?

SR BANCORP, INC. ANNOUNCES QUARTERLY FINANCIAL RESULTS
PTN

PR Newswire

a year ago

SR BANCORP, INC. ANNOUNCES QUARTERLY FINANCIAL RESULTS

Palatin Announces $10 Million Registered Direct Offering
PTN

PR Newswire

a year ago

Palatin Announces $10 Million Registered Direct Offering

Strength Seen in Repligen (RGEN): Can Its 4.3% Jump Turn into More Strength?
PTN

Zacks

a year ago

Strength Seen in Repligen (RGEN): Can Its 4.3% Jump Turn into More Strength?

Software Development Stocks Q3 Earnings: Datadog (NASDAQ:DDOG) Best of the Bunch
PTN

StockStory

a year ago

Software Development Stocks Q3 Earnings: Datadog (NASDAQ:DDOG) Best of the Bunch

Red Robin (RRGB) Gains As Market Dips: What You Should Know
PTN

Zacks

a year ago

Red Robin (RRGB) Gains As Market Dips: What You Should Know

Here's Why Aquestive Therapeutics (AQST) Fell More Than Broader Market
PTN

Zacks

a year ago

Here's Why Aquestive Therapeutics (AQST) Fell More Than Broader Market

3 Penny Stocks to Buy to Unlock 2,500% Upside Potential
PTN

InvestorPlace

a year ago

3 Penny Stocks to Buy to Unlock 2,500% Upside Potential

Federated Hermes Premier Municipal Income Fund declares dividend and announces new Trustee
PTN

PR Newswire

a year ago

Federated Hermes Premier Municipal Income Fund declares dividend and announces new Trustee

UEI Introduces Nevo® on TIDE™ Smart Thermostat Family to Create a Whole Home Controller Platform
PTN

Business Wire

a year ago

UEI Introduces Nevo® on TIDE™ Smart Thermostat Family to Create a Whole Home Controller Platform

PTN

Business Wire

a year ago

Luxfer Declares Quarterly Dividend

Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024
PTN

PR Newswire

a year ago

Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024

ICZOOM Announces SaaS Enhancement of One-Stop Components Procurement Platform to Support Customer Growth
PTN

PR Newswire

a year ago

ICZOOM Announces SaaS Enhancement of One-Stop Components Procurement Platform to Support Customer Growth

Is Now An Opportune Moment To Examine Luxfer Holdings PLC (NYSE:LXFR)?
PTN

Simply Wall St.

a year ago

Is Now An Opportune Moment To Examine Luxfer Holdings PLC (NYSE:LXFR)?

Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.
PTN

Business Wire

a year ago

Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.

PTN

Business Wire

a year ago

MFS Announces Closed-End Fund Distributions

High Tide Opens Second Canna Cabana in Kanata, Ontario
PTN

PR Newswire

a year ago

High Tide Opens Second Canna Cabana in Kanata, Ontario

Analysts Say 3 Stocks Have a Combined Upside of 3000%
PTN

InvestorPlace

a year ago

Analysts Say 3 Stocks Have a Combined Upside of 3000%

Carisma Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PTN

PR Newswire

a year ago

Carisma Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Ocugen Gains FDA Alignment on Key Aspects of OCU400—Modifier Gene Therapy—Pivotal Phase 3 Study Design
PTN

GlobeNewswire

a year ago

Ocugen Gains FDA Alignment on Key Aspects of OCU400—Modifier Gene Therapy—Pivotal Phase 3 Study Design

What Makes Myomo, Inc. (MYO) a Good Fit for 'Trend Investing'
PTN

Zacks

a year ago

What Makes Myomo, Inc. (MYO) a Good Fit for 'Trend Investing'

Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million
PTN

PR Newswire

a year ago

Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million

Share on Social Networks: